ARQT Valuation

Arcutis Biotherapeutics Inc

Add to Watchlist

Advanced Chart

14.960

+0.1(0.673%)1D

Overview
Forecast
Valuation
Earnings

ARQT Relative Valuation

ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARQT is overvalued; if below, it's undervalued.

Historical Valuation

Arcutis Biotherapeutics Inc (ARQT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.31 is considered Undervalued compared with the five-year average of -7.10. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 16.86 to 19.77 according to relative valuation methord. Compared to the current price of 14.97 USD , Arcutis Biotherapeutics Inc is Undervalued By 11.22%.

Relative Value

Fair Zone

16.86-19.77

Current Price：14.97

11.22%

Undervalued

-38.43

Trailing

Forward

-31.18

EV/EBITDA

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBITDA of -31.18. The 5-year average EV/EBITDA is -5.75. The thresholds are as follows: Strongly Undervalued below -18.79, Undervalued between -18.79 and -12.27, Fairly Valued between 0.77 and -12.27, Overvalued between 0.77 and 7.29, and Strongly Overvalued above 7.29. The current Forward EV/EBITDA of -31.18 falls within the Strongly Undervalued range.

-38.98

EV/EBIT

Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBIT of -38.98. The 5-year average EV/EBIT is -6.52. The thresholds are as follows: Strongly Undervalued below -24.03, Undervalued between -24.03 and -15.27, Fairly Valued between 2.24 and -15.27, Overvalued between 2.24 and 10.99, and Strongly Overvalued above 10.99. The current Forward EV/EBIT of -38.98 falls within the Strongly Undervalued range.

5.25

Arcutis Biotherapeutics Inc. (ARQT) has a current PS of 5.25. The 5-year average PS is 129.21. The thresholds are as follows: Strongly Undervalued below -303.48, Undervalued between -303.48 and -87.14, Fairly Valued between 345.56 and -87.14, Overvalued between 345.56 and 561.90, and Strongly Overvalued above 561.90. The current Forward PS of 5.25 falls within the Historic Trend Line -Fairly Valued range.

328.03

P/OCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/OCF of 328.03. The 5-year average P/OCF is -5.37. The thresholds are as follows: Strongly Undervalued below -70.48, Undervalued between -70.48 and -37.92, Fairly Valued between 27.18 and -37.92, Overvalued between 27.18 and 59.73, and Strongly Overvalued above 59.73. The current Forward P/OCF of 328.03 falls within the Strongly Overvalued range.

107.35

P/FCF

Arcutis Biotherapeutics Inc. (ARQT) has a current P/FCF of 107.35. The 5-year average P/FCF is 2.26. The thresholds are as follows: Strongly Undervalued below -62.21, Undervalued between -62.21 and -29.98, Fairly Valued between 34.50 and -29.98, Overvalued between 34.50 and 66.74, and Strongly Overvalued above 66.74. The current Forward P/FCF of 107.35 falls within the Strongly Overvalued range.

Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 12.41. Compared to its 3-year average P/B ratio of 6.60 , the current P/B ratio is approximately 87.89% higher. Relative to its 5-year average P/B ratio of 5.50, the current P/B ratio is about 125.53% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately -6.24%. Compared to its 3-year average FCF yield of -32.76%, the current FCF yield is approximately -80.96% lower. Relative to its 5-year average FCF yield of -24.83% , the current FCF yield is about -74.88% lower.

12.41

P/B

Median3y

6.60

Median5y

5.50

-6.31

FCF Yield

Median3y

-32.76

Median5y

-24.83

Competitors Valuation Multiple

The average P/S ratio for ARQT's competitors is 9.20, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of 5.25, which is -42.92% above the industry average. Given its robust revenue growth of 32.84%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARQT.O

Arcutis Biotherapeutics Inc

ARS Pharmaceuticals Inc

17.87

1.80B

TARS.O

Tarsus Pharmaceuticals Inc

Amicus Therapeutics Inc

Supernus Pharmaceuticals Inc

3.18

4.30%

1.87B

Performance Decomposition

Market capitalization of ARQT increased by 48.56% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -8.80 to -14.29.

The secondary factor is the Revenue Growth, contributed 32.84%to the performance.

Overall, the performance of ARQT in the past 1 year is driven by P/E Change. Which is more unsustainable.

32.84%

49.57M → 65.85M

Revenue Growth

-46.68%

-71.38 → -38.06

Margin Expansion

62.40%

-8.80 → -14.29

P/E Change

48.56%